DE60320007D1 - PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES - Google Patents
PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASESInfo
- Publication number
- DE60320007D1 DE60320007D1 DE60320007T DE60320007T DE60320007D1 DE 60320007 D1 DE60320007 D1 DE 60320007D1 DE 60320007 T DE60320007 T DE 60320007T DE 60320007 T DE60320007 T DE 60320007T DE 60320007 D1 DE60320007 D1 DE 60320007D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- respiratory diseases
- phenethanolamine derivatives
- phenethanolamine
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0225022A GB0225022D0 (en) | 2002-10-28 | 2002-10-28 | Chemical compounds |
GB0225022 | 2002-10-28 | ||
GB0225028A GB0225028D0 (en) | 2002-10-28 | 2002-10-28 | Chemical compounds |
GB0225028 | 2002-10-28 | ||
PCT/EP2003/012035 WO2004037773A1 (en) | 2002-10-28 | 2003-10-24 | Phenethanolamine derivative for the treatment of respiratory diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60320007D1 true DE60320007D1 (en) | 2008-05-08 |
DE60320007T2 DE60320007T2 (en) | 2009-06-18 |
Family
ID=32178883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60320007T Expired - Fee Related DE60320007T2 (en) | 2002-10-28 | 2003-10-24 | Phenthanolamine derivatives for the treatment of respiratory diseases |
Country Status (24)
Country | Link |
---|---|
US (1) | US7442839B2 (en) |
EP (1) | EP1556342B1 (en) |
JP (1) | JP2006503888A (en) |
KR (1) | KR20050057681A (en) |
AR (1) | AR041724A1 (en) |
AT (1) | ATE390407T1 (en) |
AU (1) | AU2003286143A1 (en) |
BR (1) | BR0315720A (en) |
CA (1) | CA2503588A1 (en) |
DE (1) | DE60320007T2 (en) |
DK (1) | DK1556342T3 (en) |
ES (1) | ES2302956T3 (en) |
HK (1) | HK1081173A1 (en) |
IS (1) | IS7814A (en) |
MA (1) | MA27697A1 (en) |
MX (1) | MXPA05004527A (en) |
NO (1) | NO20051962L (en) |
NZ (1) | NZ539676A (en) |
PL (1) | PL377122A1 (en) |
PT (1) | PT1556342E (en) |
RU (1) | RU2332400C2 (en) |
SI (1) | SI1556342T1 (en) |
TW (1) | TWI285195B (en) |
WO (1) | WO2004037773A1 (en) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1487417A4 (en) | 2001-09-17 | 2010-03-17 | Glaxo Group Ltd | Dry powder medicament formulations |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
GB0324886D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
PE20060272A1 (en) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
GT200500281A (en) | 2004-10-22 | 2006-04-24 | Novartis Ag | ORGANIC COMPOUNDS. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
ATE517908T1 (en) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | ANDROSTAN-17-ALPHA-CARBONATE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC AND INFLAMMATORY CONDITIONS |
PE20100737A1 (en) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | NEW COMPOUNDS |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
EP2281813A1 (en) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
NZ567124A (en) | 2005-10-21 | 2011-08-26 | Novartis Ag | Human antibodies against Interleukin-13 and therapeutic uses to treat asthma |
AR058109A1 (en) | 2005-12-20 | 2008-01-23 | Glaxo Group Ltd | ACID 3 - (4 - {[4 - (4 - {[3 - (3, 3 - DIMETILE - 1 - PIPERIDINIL) PROPIL] OXI} PHENYL) - 1 - PIPERIDINIL] CARBONIL} - 1 - NAFTALENIL) PROPANOIC AS ANTAGONISTS OF THE RECEIVERS OF HISTAMINE H1 / H3, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EA200801997A1 (en) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | NEW CONNECTIONS |
EP2322525B1 (en) | 2006-04-21 | 2013-09-18 | Novartis AG | Purine derivatives for use as adenosin A2A receptor agonists |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
PE20080943A1 (en) | 2006-06-23 | 2008-09-27 | Smithkline Beecham Corp | SALT TOLUENOSULPHONATE OF 4 - {[6-CHLORO-3 - ({[(2-CHLORO-3-FLUOROPHENYL) AMINO] CARBONYL} AMINO) -2-HYDROXYPHENYL] SULFONYL} -1-PIPERAZINACARBOXYLATE 1,1-DIMETHYLETHYL ANTAGON IL-8 RECEIVER |
NZ574533A (en) | 2006-08-01 | 2011-05-27 | Glaxo Group Ltd | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
ATE493174T1 (en) | 2007-01-10 | 2011-01-15 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS CHANNEL-ACTIVATE PROTEASE INHIBITORS |
AR065804A1 (en) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT |
CN101687851B (en) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | Organic compounds |
AU2008334629B2 (en) | 2007-12-10 | 2012-04-12 | Novartis Ag | Organic compounds |
CN101910153B (en) | 2008-01-11 | 2014-01-22 | 诺华股份有限公司 | Pyrimidines as kinase inhibitors |
KR20160129109A (en) | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-lipoxygenase-activating protein inhibitor |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
US8236808B2 (en) | 2008-06-10 | 2012-08-07 | Novartis Ag | Pyrazine derivatives as ENAC blockers |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
CA2748331C (en) | 2008-12-30 | 2016-08-02 | Pulmagen Therapeutics (Inflammation) Limited | Sulfonamide compounds for the treatment of respiratory disorders |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
ES2542551T3 (en) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-yl-indazoles as inhibitors of PI3 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
JP2012520845A (en) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Pyrimidine derivatives used as Itk inhibitors |
US20120016011A1 (en) | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CN102439151A (en) | 2009-03-19 | 2012-05-02 | 默沙东公司 | Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina) sequence listing |
JP2012520686A (en) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of signal transduction transcription factor 6 (STAT6) gene expression using small interfering nucleic acids (siNA) |
US20120004282A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp, | RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521762A (en) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | RNA interference-mediated inhibition of nerve growth factor β chain (NGFβ) gene expression using small interfering nucleic acids (siNA) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120022142A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US20100273744A1 (en) | 2009-04-24 | 2010-10-28 | Paul Martin Gore | Compounds |
JP2012524754A (en) | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | Pyrazole and triazolcarboxamides as CRAC channel inhibitors |
EA021056B1 (en) | 2009-04-30 | 2015-03-31 | Глаксо Груп Лимитед | Oxazole substituted indazoles as pi3-kinase inhibitors, pharmaceutical composition comprising same and use thereof in treatment of disorders mediated by inappropriate pi3-kinase activity |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
JP2013508414A (en) | 2009-10-22 | 2013-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compositions for the treatment of cystic fibrosis and other chronic diseases |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
JP2013512879A (en) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Benzpyrazole derivatives as inhibitors of PI3 kinase |
WO2011084316A2 (en) | 2009-12-16 | 2011-07-14 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
DK2614058T3 (en) | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
GEP20156285B (en) | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
JP2014507458A (en) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Pyrido [3,4-B] pyrazine derivatives as Syk inhibitors |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
JP6165733B2 (en) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | N-substituted heterocyclylcarboxamides |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
CA2925064A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
JP6404944B2 (en) | 2014-04-24 | 2018-10-17 | ノバルティス アーゲー | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
PT3134396T (en) | 2014-04-24 | 2019-12-16 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
CN107072976A (en) | 2014-05-12 | 2017-08-18 | 葛兰素史克知识产权第二有限公司 | The pharmaceutical composition for including Danirixin for treating communicable disease |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP2019524792A (en) | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Compound |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
JOP20220044A1 (en) | 2019-08-28 | 2023-01-30 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
WO2023097697A1 (en) * | 2021-12-03 | 2023-06-08 | 广东莱佛士制药技术有限公司 | Method for synthesizing (1r)-1-(2,2-dimethyl-4h-1,3-benzodioxin-6-yl)oxazolidin-2-one |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2918408A (en) | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
FI79651C (en) | 1982-10-08 | 1990-02-12 | Glaxo Group Ltd | Dosing device for medicine |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
EP0162576B1 (en) | 1984-04-17 | 1989-07-26 | Glaxo Group Limited | Ethanolamine compounds |
IL74940A (en) | 1984-04-17 | 1988-06-30 | Glaxo Group Ltd | Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them |
KR910000932B1 (en) | 1984-04-18 | 1991-02-19 | 가부시기가이샤 다이킨세이사꾸쇼 | Rower transfer device |
ES8609216A1 (en) | 1984-07-13 | 1986-09-01 | Glaxo Group Ltd | Aminophenol compounds |
GB8426191D0 (en) | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
GR861995B (en) | 1985-07-30 | 1986-11-04 | Glaxo Group Ltd | Devices for administering medicaments to patients |
EP0220054A3 (en) | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives |
GB2230523A (en) | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
EP0633776B1 (en) | 1992-04-02 | 2001-05-09 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5998428A (en) | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
EP0947498B1 (en) | 1996-12-02 | 2004-09-15 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same |
JP2001507704A (en) | 1996-12-30 | 2001-06-12 | アメリカン・ホーム・プロダクツ・コーポレイション | Substituted benzo [1,4] dioxane as antiobesity drug |
GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
PT1070056E (en) | 1998-03-14 | 2004-11-30 | Altana Pharma Ag | PDE III / IV INHIBITORS BASED ON FTALAZINONE |
AR035987A1 (en) | 1999-03-01 | 2004-08-04 | Smithkline Beecham Corp | USE OF A PDE 4 INHIBITING COMPOUND FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND THE MEDICINAL PRODUCT TO TREAT ASTHMA INDUCED BY EXERCISE |
ATE447952T1 (en) | 1999-08-21 | 2009-11-15 | Nycomed Gmbh | SYNERGISTIC COMBINATION OF PUMAFENTRINE AND SALMETEROL |
GB0014546D0 (en) | 2000-06-14 | 2000-08-09 | Glaxo Group Ltd | A novel process |
GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
PT1425001E (en) * | 2001-09-14 | 2009-02-18 | Glaxo Group Ltd | Phenethanolamine derivatives for treatment of respiratory diseases |
AU2003298094A1 (en) | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Medicinal arylethanolamine compounds |
-
2003
- 2003-10-24 DE DE60320007T patent/DE60320007T2/en not_active Expired - Fee Related
- 2003-10-24 EP EP03776873A patent/EP1556342B1/en not_active Expired - Lifetime
- 2003-10-24 ES ES03776873T patent/ES2302956T3/en not_active Expired - Lifetime
- 2003-10-24 US US10/532,869 patent/US7442839B2/en not_active Expired - Fee Related
- 2003-10-24 KR KR1020057007275A patent/KR20050057681A/en not_active Application Discontinuation
- 2003-10-24 WO PCT/EP2003/012035 patent/WO2004037773A1/en active IP Right Grant
- 2003-10-24 JP JP2004546022A patent/JP2006503888A/en active Pending
- 2003-10-24 PT PT03776873T patent/PT1556342E/en unknown
- 2003-10-24 SI SI200331215T patent/SI1556342T1/en unknown
- 2003-10-24 AU AU2003286143A patent/AU2003286143A1/en not_active Abandoned
- 2003-10-24 MX MXPA05004527A patent/MXPA05004527A/en active IP Right Grant
- 2003-10-24 RU RU2005111975/04A patent/RU2332400C2/en not_active IP Right Cessation
- 2003-10-24 AR ARP030103896A patent/AR041724A1/en unknown
- 2003-10-24 CA CA002503588A patent/CA2503588A1/en not_active Abandoned
- 2003-10-24 AT AT03776873T patent/ATE390407T1/en not_active IP Right Cessation
- 2003-10-24 NZ NZ539676A patent/NZ539676A/en unknown
- 2003-10-24 PL PL377122A patent/PL377122A1/en not_active Application Discontinuation
- 2003-10-24 DK DK03776873T patent/DK1556342T3/en active
- 2003-10-24 BR BR0315720-2A patent/BR0315720A/en not_active IP Right Cessation
- 2003-10-27 TW TW092129753A patent/TWI285195B/en not_active IP Right Cessation
-
2005
- 2005-04-20 IS IS7814A patent/IS7814A/en unknown
- 2005-04-21 NO NO20051962A patent/NO20051962L/en not_active Application Discontinuation
- 2005-05-11 MA MA28274A patent/MA27697A1/en unknown
-
2006
- 2006-01-24 HK HK06101090A patent/HK1081173A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200418772A (en) | 2004-10-01 |
RU2005111975A (en) | 2006-01-20 |
MA27697A1 (en) | 2006-01-02 |
US7442839B2 (en) | 2008-10-28 |
DK1556342T3 (en) | 2008-07-21 |
US20060205794A1 (en) | 2006-09-14 |
DE60320007T2 (en) | 2009-06-18 |
NO20051962L (en) | 2005-05-19 |
MXPA05004527A (en) | 2005-07-26 |
CA2503588A1 (en) | 2004-05-06 |
PL377122A1 (en) | 2006-01-23 |
AR041724A1 (en) | 2005-05-26 |
ATE390407T1 (en) | 2008-04-15 |
RU2332400C2 (en) | 2008-08-27 |
WO2004037773A1 (en) | 2004-05-06 |
BR0315720A (en) | 2005-09-06 |
AU2003286143A1 (en) | 2004-05-13 |
EP1556342A1 (en) | 2005-07-27 |
KR20050057681A (en) | 2005-06-16 |
TWI285195B (en) | 2007-08-11 |
WO2004037773A8 (en) | 2004-07-22 |
HK1081173A1 (en) | 2006-05-12 |
IS7814A (en) | 2005-04-20 |
JP2006503888A (en) | 2006-02-02 |
SI1556342T1 (en) | 2008-08-31 |
PT1556342E (en) | 2008-04-28 |
NZ539676A (en) | 2006-10-27 |
ES2302956T3 (en) | 2008-08-01 |
EP1556342B1 (en) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60320007D1 (en) | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | |
DE60230425D1 (en) | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | |
DE602004020072D1 (en) | 1,2,3,4-TETRASUBSTITUTED INDOL FOR THE TREATMENT OF RESPIRATORY DISEASES | |
NO20033594L (en) | Phenethanolamine derivatives for the treatment of respiratory diseases | |
ATE447551T1 (en) | BIPHENYLOXYACETIC ACID - DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | |
DE602004028763D1 (en) | TE FOR THE TREATMENT OF VIRUS DISEASES | |
DE602004029580D1 (en) | SUBSTITUTED INDOIND DERIVATIVES FOR A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES | |
DE60124302D1 (en) | THIAZONE DERIVATIVES FOR THE TREATMENT OF PPAR-LIFE DISEASES | |
DE60303238D1 (en) | Pyrimidine-acetic acid derivatives suitable for the treatment of CRTH2-related diseases | |
ATE476414T1 (en) | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | |
ATE440866T1 (en) | NOGO-A-NEUTRALIZING IMMUNOLOBULINES FOR THE TREATMENT OF NEUROLOGICAL DISEASES | |
ATE417037T1 (en) | DIARYLUREA DERIVATIVES SUITABLE FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES | |
ATE517085T1 (en) | PHENOXYACETIC ACID DERIVATIVES SUITABLE FOR THE TREATMENT OF RESPIRATORY DISEASES | |
DE60328476D1 (en) | MEDICAL BALLOON SYSTEM FOR THE TREATMENT OF ADIPOSITAS | |
ATE369333T1 (en) | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | |
ATE375977T1 (en) | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | |
DE602005017636D1 (en) | NEW HYDANTINE DERIVATIVES FOR THE TREATMENT OF OBSTRUCTIVE RESPIRATORY DISEASES | |
DE60322451D1 (en) | 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain | |
ATE443704T1 (en) | PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISEASES | |
DE60204466D1 (en) | INTEGRINMA TREATMENT FOR THE TREATMENT OF EYE DISEASES | |
DE60236743D1 (en) | FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES | |
DE50013843D1 (en) | MEDICAMENT FOR THE TREATMENT OF DARMER DISEASES | |
ATE330596T1 (en) | USE OF 3-BEZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISEASES | |
ATE482707T1 (en) | 1-Ä2H-1-BENZOPYRAN-2-ON-8-YLÜ-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF PAIN | |
DE60311822D1 (en) | NEW PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: PROCOPIOU, PANAYIOTIS ALEXANDROU, STEVENAGE, H, GB Inventor name: LOOKER, BRIAN EDGAR, STEVENAGE, HERTFORDSHIRE, GB Inventor name: GUNTRIP, STEPHEN BARRY, STEVENAGE, HERTFORDSHI, GB Inventor name: CHAPMAN, ALAN MICHAEL, TONBRIDGE, KENT, GB |
|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |